Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:CRSP NASDAQ:EDIT NASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$20.30+5.8%$17.64$13.53▼$35.25$1.93B2.071.53 million shs3.07 million shsCRSPCRISPR Therapeutics$54.82+7.1%$41.29$30.04▼$63.68$4.42B1.821.91 million shs3.77 million shsEDITEditas Medicine$2.86+12.6%$1.90$0.91▼$6.05$212.63M2.152.62 million shs5.70 million shsNTLAIntellia Therapeutics$11.12+8.5%$8.87$5.90▼$28.18$1.06B2.213.00 million shs6.60 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+5.84%+15.80%+9.26%+24.01%-14.88%CRSPCRISPR Therapeutics+7.09%+13.01%+30.96%+57.12%+2.99%EDITEditas Medicine+12.60%+27.11%+49.74%+148.70%-40.66%NTLAIntellia Therapeutics+8.49%+12.55%+37.45%+57.06%-51.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBEAMBeam Therapeutics2.4724 of 5 stars3.51.00.00.02.52.50.6CRSPCRISPR Therapeutics2.9794 of 5 stars4.31.00.00.01.92.50.6EDITEditas Medicine4.1811 of 5 stars3.23.00.04.32.02.50.6NTLAIntellia Therapeutics4.6881 of 5 stars4.33.00.04.72.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.00Buy$48.75140.15% UpsideCRSPCRISPR Therapeutics 2.53Moderate Buy$71.7530.88% UpsideEDITEditas Medicine 2.31Hold$4.7064.34% UpsideNTLAIntellia Therapeutics 2.65Moderate Buy$33.37200.08% UpsideCurrent Analyst Ratings BreakdownLatest EDIT, BEAM, CRSP, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/27/2025CRSPCRISPR TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.006/27/2025CRSPCRISPR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$86.006/27/2025CRSPCRISPR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$65.006/26/2025CRSPCRISPR TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$81.006/26/2025CRSPCRISPR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$82.006/16/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$7.006/16/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/3/2025NTLAIntellia TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$74.00 ➝ $54.005/29/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral$10.00 ➝ $7.005/29/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.52M32.14N/AN/A$8.86 per share2.29CRSPCRISPR Therapeutics$37.31M126.89N/AN/A$22.64 per share2.42EDITEditas Medicine$32.31M7.41N/AN/A$1.63 per share1.75NTLAIntellia Therapeutics$57.88M19.90N/AN/A$8.56 per share1.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$376.74M-$4.61N/AN/AN/A-609.24%-44.24%-30.97%8/5/2025 (Estimated)CRSPCRISPR Therapeutics-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)EDITEditas Medicine-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)NTLAIntellia Therapeutics-$519.02M-$5.23N/AN/AN/A-1,154.10%-56.06%-44.25%8/14/2025 (Estimated)Latest EDIT, BEAM, CRSP, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025N/AEDITEditas Medicine-$0.40N/AN/AN/A$1.81 millionN/A8/5/2025Q2 2025BEAMBeam Therapeutics-$1.04N/AN/AN/A$13.29 millionN/A8/4/2025Q2 2025CRSPCRISPR Therapeutics-$1.54N/AN/AN/A$6.44 millionN/A5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million5/6/2025Q1 2025CRSPCRISPR Therapeutics-$1.27-$1.58-$0.31-$1.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam TherapeuticsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A8.818.81CRSPCRISPR TherapeuticsN/A15.6415.64EDITEditas MedicineN/A3.083.08NTLAIntellia TherapeuticsN/A4.904.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%CRSPCRISPR Therapeutics69.20%EDITEditas Medicine71.90%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.50%CRSPCRISPR Therapeutics4.10%EDITEditas Medicine1.90%NTLAIntellia Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510100.56 million97.04 millionOptionableCRSPCRISPR Therapeutics46086.36 million82.82 millionOptionableEDITEditas Medicine23083.71 million82.12 millionOptionableNTLAIntellia Therapeutics600103.58 million100.37 millionOptionableEDIT, BEAM, CRSP, and NTLA HeadlinesRecent News About These CompaniesIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6.1% - Should You Buy?July 8 at 12:39 PM | marketbeat.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 7 at 4:01 PM | globenewswire.comIntellia Gains 29.8% in a Month: How Should You Play the Stock?July 7 at 10:50 AM | zacks.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Eliana Clark Sells 1,022 SharesJuly 4, 2025 | insidertrades.comIntellia Therapeutics Inc. Advanced Charts | NTLA | Barron'sJuly 4, 2025 | barrons.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Sumitomo Mitsui Trust Group Inc.July 4, 2025 | marketbeat.comCitizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z DataJuly 3, 2025 | msn.comInsider Selling: Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Sells $10,036.04 in StockJuly 3, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube Sells 2,503 SharesJuly 3, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Director Sells $14,278.81 in StockJuly 2, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6.8% - Here's WhyJuly 2, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 29, 2025 | marketbeat.comCRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - NasdaqJune 27, 2025 | nasdaq.comNTLA - Intellia Therapeutics Inc Chart - MorningstarJune 26, 2025 | morningstar.comMCRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?June 25, 2025 | zacks.comIntellia Therapeutics, Inc. (NTLA) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNTLA Intellia Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comWill Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?June 21, 2025 | finance.yahoo.comIntellia Therapeutics (NASDAQ:NTLA) Shares Down 6.4% - What's Next?June 20, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside PotentialJune 19, 2025 | finance.yahoo.comWedbush Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA)June 18, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeCapitalize on Volatility: 3 Finance Stocks Thriving in 2025By Chris Markoch | July 2, 2025View Capitalize on Volatility: 3 Finance Stocks Thriving in 2025EV Tax Credits Are Ending—Here’s Why These 2 Stocks Could SoarBy Leo Miller | July 8, 2025View EV Tax Credits Are Ending—Here’s Why These 2 Stocks Could SoarEDIT, BEAM, CRSP, and NTLA Company DescriptionsBeam Therapeutics NASDAQ:BEAM$20.30 +1.12 (+5.84%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$20.65 +0.35 (+1.72%) As of 07/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.CRISPR Therapeutics NASDAQ:CRSP$54.82 +3.63 (+7.09%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$54.98 +0.16 (+0.28%) As of 07/8/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Editas Medicine NASDAQ:EDIT$2.86 +0.32 (+12.60%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$2.94 +0.08 (+2.62%) As of 07/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Intellia Therapeutics NASDAQ:NTLA$11.12 +0.87 (+8.49%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$11.20 +0.09 (+0.76%) As of 07/8/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
